• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>AstraZeneca PLC ADR

AstraZeneca PLC ADR

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. AstraZeneca PLC Acquisition of Rights to Actavis' Portfolio

    AstraZeneca PLC Acquisition of Rights to Actavis' Portfolio

  2. AstraZeneca : US Court Rules Pulmicort Respules Patent Invalid

    AstraZeneca : US Court Rules Pulmicort Respules Patent Invalid

  3. Orca Pharmaceuticals and AstraZeneca Announce Development Partnership to Identify Best-in-Class RORγ Inhibitors to Treat Autoimmune Disease

    Orca Pharmaceuticals and AstraZeneca Announce Development Partnership to Identify Best-in-Class RORγ Inhibitors to Treat Autoimmune Disease

  4. ADDING MULTIMEDIA AstraZeneca HealthCare Foundation Awards $223,000 Grant to Ashland-Boyd County Health Department to Improve Heart Health

    ADDING MULTIMEDIA AstraZeneca HealthCare Foundation Awards $223,000 Grant to Ashland-Boyd County Health Department to Improve Heart Health

  5. ADDING MULTIMEDIA AstraZeneca HealthCare Foundation Awards $250,000 Grant to St. Mary’s Health Wagon to Improve Heart Health

    ADDING MULTIMEDIA AstraZeneca HealthCare Foundation Awards $250,000 Grant to St. Mary’s Health Wagon to Improve Heart Health

  6. Research and Markets: Global Pharma US & EU Outlook 2015: First-In-Class Innovations and Cost Optimization Plays Major Role in Shaping up Business for Large Cap Pharmaceutical Companies

    Research and Markets: Global Pharma US & EU Outlook 2015: First-In-Class Innovations and Cost Optimization Plays Major Role in Shaping up Business for Large Cap Pharmaceutical Companies

  7. Research and Markets: Global Alcohol Addiction Therapeutics Pipeline Review 2015 - 23 Companies 35 Drug Profiles

    Research and Markets: Global Alcohol Addiction Therapeutics Pipeline Review 2015 - 23 Companies 35 Drug Profiles

  8. Research and Markets: Generic Drugs a $350 Billion Opportunity According to 'The Generic Drugs Market: 2015-2030 - Opportunities, Challenges, Strategies & Forecasts'

    Research and Markets: Generic Drugs a $350 Billion Opportunity According to 'The Generic Drugs Market: 2015-2030 - Opportunities, Challenges, Strategies & Forecasts'

  9. Research and Markets: Urinary Tract Infections Therapeutics Pipeline Review 2015 - 22 Companies & 33 Drug Profiles

    Research and Markets: Urinary Tract Infections Therapeutics Pipeline Review 2015 - 22 Companies & 33 Drug Profiles

  10. Research and Markets: Ventilator Associated Pneumonia (VAP) Therapeutics Pipeline Review 2015 - 13 Companies & 19 Drug Profiles

    Research and Markets: Ventilator Associated Pneumonia (VAP) Therapeutics Pipeline Review 2015 - 13 Companies & 19 Drug Profiles

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.